Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples

31Citations
Citations of this article
13Readers
Mendeley users who have this article in their library.
Get full text

Abstract

Aim: To investigate the possible correlation of nucleophosmin/B23 expression with bladder carcinoma recurrence. Methods: Surgically-resected bladder tumors staged pTa to pT4 were examined for nucleophosmin/B23 expression by immuno-histochemistry. The study group consisted of 132 consecutive patients surgically treated at Chang Gung Memorial Hospital between December 1998 and November 1999. The mean follow up was 72 months (range: 48-84 months). Results: Nuclear nucleophosmin/B23 staining was detected in 96% of advanced stage and poorly-differentiated tumors. Higher nucleophosmin/B23 levels were linked to more advanced tumor stages, grades, poor prognosis, and likelihood of recurrence (P<0.05). The Cox multivariate analysis indicated the nucleophosmin/B23 expression as an independent indicator for tumor recurrence (P=0.009). Conclusion: The results suggest that nucleophosmin/B23 is a favorable prognostic indicator for bladder cancer. Nucleophosmin/B23 could be a useful molecular tumor marker for predicting bladder cancer recurrence. © 2008 CPS and SIMM.

Cite

CITATION STYLE

APA

Tsui, K. H., Juang, H. H., Lee, T. H., Chang, P. L., Chen, C. L., & Yung, B. Y. M. (2008). Association of nucleophosmin/B23 with bladder cancer recurrence based on immunohistochemical assessment in clinical samples. Acta Pharmacologica Sinica, 29(3), 364–370. https://doi.org/10.1111/j.1745-7254.2008.00747.x

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free